These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37846599)

  • 1. Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma.
    Sverrild A; Cerps S; Nieto-Fontarigo JJ; Ramu S; Hvidtfeldt M; Menzel M; Kearley J; Griffiths JM; Parnes JR; Porsbjerg C; Uller L
    Allergy; 2024 Mar; 79(3):656-666. PubMed ID: 37846599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
    Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
    Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
    Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sounding the alarmins-The role of alarmin cytokines in asthma.
    Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
    Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial cells from donors with asthma.
    Uller L; Leino M; Bedke N; Sammut D; Green B; Lau L; Howarth PH; Holgate ST; Davies DE
    Thorax; 2010 Jul; 65(7):626-32. PubMed ID: 20627922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R; Lugogo N; Corren J; Ambrose CS
    J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
    Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
    Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
    [No Abstract]   [Full Text] [Related]  

  • 10. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
    Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins.
    Varricchi G; Poto R
    Eur J Intern Med; 2024 Jul; 125():28-31. PubMed ID: 38762432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positioning of Tezepelumab in Severe Asthma.
    Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
    J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
    Shinkai M; Yabuta T
    Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.
    Duchesne M; Okoye I; Lacy P
    Front Immunol; 2022; 13():975914. PubMed ID: 36311787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
    Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative Stress Attenuates TLR3 Responsiveness and Impairs Anti-viral Mechanisms in Bronchial Epithelial Cells From COPD and Asthma Patients.
    Menzel M; Ramu S; Calvén J; Olejnicka B; Sverrild A; Porsbjerg C; Tufvesson E; Bjermer L; Akbarshahi H; Uller L
    Front Immunol; 2019; 10():2765. PubMed ID: 31849956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezepelumab for asthma.
    Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
    Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
    Schleich F; Sabbe M; Moermans C; Louis R
    Rev Med Liege; 2024 Jan; 79(1):60-64. PubMed ID: 38223972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma.
    Cerps S; Sverrild A; Ramu S; Nieto-Fontarigo JJ; Akbarshahi H; Menzel M; Andersson C; Tillgren S; Hvidtfeldt M; Porsbjerg C; Uller L
    Allergy; 2022 Aug; 77(8):2498-2508. PubMed ID: 35114024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses.
    Ramu S; Akbarshahi H; Mogren S; Berlin F; Cerps S; Menzel M; Hvidtfeldt M; Porsbjerg C; Uller L; Andersson CK
    BMC Immunol; 2021 Jun; 22(1):35. PubMed ID: 34078278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.